Lilly receives US FDA fast track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related co-morbidities

Eli Lilly

6 October 2022 - The fast track designation accelerates tirzepatide's path to US FDA submission for the treatment of adults with obesity, or overweight with weight-related co-morbidities

Eli Lilly announced today that the US FDA has granted fast track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related co-morbidities.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track